How Genes Influence Drug Response
Your genes provide the instructions for making proteins, and many of these proteins are involved in how your body handles and responds to medicines. Genetic differences (variations) can lead to differences in these proteins, which in turn affect your response to a drug. This happens primarily in three main ways:
1. Pharmacokinetics (PK) – “What the body does to the drug”
Genes influence how the body absorbs, distributes, metabolizes, and excretes a drug. The most common impact is on drug metabolism.
- Example: The CYP450 Enzyme Family
- Normal Metabolizers: Most people have enzymes that work at a standard rate.
- Poor Metabolizers: Some people have genetic variants that create slow-working or non-functioning enzymes. This can cause the drug to build up in their body, leading to toxicity and overdose even at standard doses.
- Ultra-rapid Metabolizers: Others have genetic variants that create very fast-working enzymes. This can cause the drug to be broken down too quickly, resulting in no therapeutic effect and treatment failure.
- Real-World Example: The blood thinner Warfarin. Variants in the CYP2C9 gene affect how quickly it is metabolized. Poor metabolizers require a much lower dose to avoid dangerous bleeding.
2. Pharmacodynamics (PD) – “What the drug does to the body”
Genes influence the drug’s target, such as a receptor or an enzyme in the body. A genetic variation can make this target more or less sensitive to the drug.
- Real-World Example: The blood thinner Clopidogrel. It is a prodrug that must be activated by the enzyme CYP2C19 to work. Poor metabolizers with variants in the CYP2C19 gene cannot activate the drug effectively, leaving them at a higher risk of heart attacks and strokes because the drug doesn’t work for them.
3. Immune-Mediated Reactions
Some genes, particularly those in the Human Leukocyte Antigen (HLA) system, can make a person’s immune system more likely to mistakenly recognize a drug as a foreign invader, triggering a severe allergic or hypersensitivity reaction.
- Real-World Example: The HIV drug Abacavir. Patients with the HLA-B*57:01 variant have a very high risk of a potentially fatal hypersensitivity reaction. Screening for this variant before prescribing is now standard practice.
Integration into Pharmacovigilance Activities
Traditionally, pharmacovigilance has been reactive—collecting and analyzing reports of adverse drug reactions (ADRs) after they occur. Pharmacogenomics makes it proactive and predictive.
Here’s how it’s integrated, as outlined in the EMA guideline:
1. Risk Management Planning (RMP)
- Safety Specification: When a new drug is approved, its RMP must now consider genetic factors. It should state if there are “identified risks” (e.g., we know poor metabolizers are at risk) or “potential risks/missing information” (e.g., we suspect a genetic link but need more data) for certain subpopulations.
- Pharmacovigilance Plan: This plan includes activities to investigate genetic signals. This could involve:
- Targeted Studies: Conducting Post-Authorisation Safety Studies (PASS) that specifically collect genetic data from patients who experience an ADR to look for common genetic variants.
- Genetic Sampling: Systematically collecting DNA samples from patients in clinical trials or post-marketing studies to build a database for future analysis.
2. Signal Detection and Evaluation
- When a cluster of unexpected or severe ADRs is reported, pharmacovigilance scientists now ask, “Could this be genetic?”
- They can analyze the genetic data (if collected) from these patients to see if a specific biomarker (e.g., a gene variant) is overrepresented compared to patients who did not have the reaction.
- This helps move from seeing an ADR as a random “idiosyncratic” event to understanding it as a predictable one in a genetically defined group.
3. Risk Minimization and Labelling
This is the most critical outcome. Based on the evidence, regulatory authorities take action to protect patients.
- Product Labeling (SmPC): Genetic information is added to the drug’s label to guide doctors. This can be:
- A Contraindication: “Do not use this drug in patients with the XYZ genetic variant.”
- A Dosing Recommendation: “Patients who are CYP2D6 poor metabolizers should receive a 50% lower dose.”
- A Warning/Precaution: “Test for HLA-B*15:02 variant in patients of Asian ancestry before starting treatment.”
- Educational Materials: For complex genetic risks, additional materials are sent to healthcare professionals to ensure they understand the new testing and dosing requirements.
In essence, pharmacogenomics transforms pharmacovigilance by:
- Explaining the Unexplained: Providing a biological reason for why certain individuals experience severe side effects or treatment failure.
- Shifting from Reactive to Proactive: Allowing for the prediction and prevention of ADRs before a drug is prescribed, through genetic testing.
- Enabling Personalized Medicine: Moving away from a “one-size-fits-all” dosing model to tailored therapies based on an individual’s genetic makeup, thereby improving both drug safety and efficacy.
This EMA guideline establishes a proactive, life-cycle approach to using pharmacogenomics to make drug therapy safer. It provides a clear pathway from identifying a genetic safety signal to implementing and monitoring concrete actions in clinical practice.
